Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Free Report) were up 4.6% during mid-day trading on Wednesday. The company traded as high as $11.03 and last traded at $11.22. 121,339 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 1,265,104 shares. The stock had previously closed at $10.73.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on ZVRA. Guggenheim cut their price target on Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating for the company in a report on Friday, August 7th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research note on Thursday, August 20th. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $27.14.
Zevra Therapeutics Trading Up 4.2%
Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. On average, equities analysts expect that Zevra Therapeutics, Inc. will post 0.72 earnings per share for the current fiscal year.
Insider Transactions at Zevra Therapeutics
In related news, Director Corey Watton sold 12,300 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the transaction, the director owned 1,800 shares in the company, valued at approximately $20,250. This trade represents a 87.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 3.70% of the company’s stock.
Hedge Funds Weigh In On Zevra Therapeutics
A number of hedge funds have recently made changes to their positions in the business. Tidal Investments LLC acquired a new position in Zevra Therapeutics during the 2nd quarter worth approximately $150,000. WINTON GROUP Ltd raised its stake in shares of Zevra Therapeutics by 49.0% during the second quarter. WINTON GROUP Ltd now owns 24,335 shares of the company’s stock valued at $349,000 after purchasing an additional 8,001 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Zevra Therapeutics during the second quarter worth $28,000. Wellington Management Group LLP boosted its stake in shares of Zevra Therapeutics by 5.2% in the second quarter. Wellington Management Group LLP now owns 164,538 shares of the company’s stock valued at $2,359,000 after purchasing an additional 8,121 shares during the period. Finally, Globeflex Capital L P acquired a new stake in Zevra Therapeutics during the 2nd quarter valued at $2,752,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.
Zevra Therapeutics Company Profile
Zevra Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company seeks to address conditions with significant unmet medical needs by combining patient-focused drug development with proprietary technologies designed to improve the delivery and development of medicines.
Zevra’s lead product is MIPLYFFA (arimoclomol), which the U.S. Food and Drug Administration approved in 2024 for the treatment of Niemann-Pick disease type C in adults and children two years of age and older, in combination with miglustat.
Read More
- Five stocks we like better than Zevra Therapeutics
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
- Morgan Stanley Is Bullish on Apple—But With a Catch
- Disney Is Opening the Door to Netflix—and Changing the Streaming Playbook
- DraftKings Stacks the Deck: The $800M Prediction Pivot
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
